Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
- PMID: 19949171
- DOI: 10.1136/ebm.14.6.168
Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
Comment on
-
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6. Lancet. 2009. PMID: 19501900 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous